首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1548159

全球肝癌诊断市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Liver Cancer Diagnostic Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球肝癌诊断市场需求预计将从2023年的938909万美元达到2032年近1825896万美元的市场规模，2024-2032年研究期间复合年增长率为7.67%。

肝癌诊断是指用于检测和确认肝癌（也称为肝细胞癌）存在的方法和程序。此诊断过程通常涉及影像技术的组合，包括电脑断层扫描 (CT)、超音波和磁振造影 (MRI)，以可视化肿瘤并评估其范围。血液检查，包括肝功能检查和甲胎蛋白 (AFP) 等生物标记物，有助于评估肝臟健康状况和癌症的存在。准确的诊断通常需要进行活检，即透过显微镜检查组织样本中的癌细胞。及时、准确的诊断对于有效治疗和更好的结果至关重要。

市场动态

由于全球肝癌盛行率不断上升，肝癌诊断市场正在经历成长。乙型和丙型肝炎感染率上升、饮酒量增加和肥胖等因素导致肝癌发病率不断上升，从而导致对有效诊断解决方案的需求增加。早期检测可以提高治疗效果，从而推动对先进诊断技术的需求。技术进步为市场带来了重大机会。影像技术的创新，例如高解析度 MRI 和先进的超音波技术，可以提供更准确、更详细的肝臟肿瘤可视化。此外，开发非侵入性诊断测试（例如液体活检和分子生物标记）为传统活检方法提供了一个有希望的替代方案，提高了患者的舒适度和诊断准确性。

肿瘤学中对个人化医疗的日益重视为肝癌诊断创造了更多机会。遗传和基因组测试的进步可以识别特定的肿瘤特征和突变，从而实现量身定制的治疗方法并改善患者管理。这一趋势支持了对提供全面分子和遗传资讯的先进诊断工具的需求。扩大新兴市场的医疗保健基础设施和增加医疗保健投资有助于市场成长。随着这些地区发展医疗保健系统并增加获得诊断技术的机会，对肝癌诊断的需求预计将会上升。此外，有关肝癌及其危险因素的认识和教育计划的兴起增强了早期发现工作。促进筛检和早期诊断的公共卫生措施透过增加诊断测试的采用来进一步支持市场成长。然而，与先进诊断技术相关的高成本以及服务欠缺地区获得医疗保健的机会有限可能会抑制市场成长。

这项详细的市场研究以从多个来源获得的资料为中心，并使用多种工具进行分析，包括波特五力分析、市场吸引力分析和价值链分析。这些工具用于深入了解市场的潜在价值，为业务策略家提供最新的成长机会。此外，这些工具还提供了全球肝癌诊断市场中每个应用/产品细分的详细分析。

市场区隔

广泛的肝癌诊断市场已细分为测试类型和最终用户。该报告根据地理细分研究了这些子集。策略师可以获得详细的洞察并针对特定市场制定适当的策略。这些细节将导致采取有针对性的方法，从而识别更好的机会。

按测试类型

实验室检验（生物标记、血液检验）
影像学
内视镜检查
活检
其他的

按最终用途

医院和诊断实验室
学术及研究机构
製药和 CRO 实验室
区域分析
此外，该报告还进行了地理细分，主要关注北美、欧洲、亚太地区、拉丁美洲以及中东和非洲地区肝癌诊断的当前和预测需求。该报告进一步关注所有地区对各个应用领域的需求。
该报告还涵盖了详细的竞争格局，包括在全球市场上运营的主要参与者的公司简介。肝癌诊断市场的主要参与者包括 Abbott Laboratories、F. Hoffmann-La Roche Ltd.、Qiagen NV、Thermo Fisher Scientific Inc.、Siemens Healthineers、Becton Dickinson & Company、Illumina Inc.、Koninklijke Philips NV、Epigenomics AG、 Fujifilm Medical Inc. Systems USA Inc. 深入了解竞争前景，包括未来产能、关键併购、财务概览、合作伙伴关係、合作、新产品发布、新产品开发和其他发展，并提供总部信息

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：肝癌诊断公司的竞争格局

肝癌诊断市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Abbott Laboratories

公司概况
公司收入
产品
最新动态

F. Hoffmann-La Roche Ltd.

公司概况
公司收入
产品
最新动态

Qiagen NV

公司概况
公司收入
产品
最新动态

Thermo Fisher Scientific Inc.

公司概况
公司收入
产品
最新动态

Siemens Healthineers

公司概况
公司收入
产品
最新动态

Becton Dickinson & Company

公司概况
公司收入
产品
最新动态

Illumina Inc.

公司概况
公司收入
产品
最新动态

Koninklijke Philips NV

公司概况
公司收入
产品
最新动态

Epigenomics AG

公司概况
公司收入
产品
最新动态

Fujifilm Medical Systems USA Inc.

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11210557

The global demand for Liver Cancer Diagnostic Market is presumed to reach the market size of nearly USD 18258.96 Million by 2032 from USD 9389.09 Million in 2023 with a CAGR of 7.67% under the study period 2024 - 2032..

Liver cancer diagnostic refers to the methods and procedures used to detect & confirm the presence of liver cancer, also known as hepatocellular carcinoma. This diagnostic process typically involves a combination of imaging techniques, including computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), to visualize tumors and assess their extent. Blood tests, including liver function tests and biomarkers like alpha-fetoprotein (AFP), help evaluate liver health and cancer presence. An accurate diagnosis frequently necessitates a biopsy, where a tissue sample is examined microscopically for cancer cells. Timely & precise diagnosis is integral for effective treatment & better outcomes.

Market Dynamics

The liver cancer diagnostic market is experiencing growth fuelled by the rising prevalence of liver cancer worldwide. Factors such as rising rates of hepatitis B & C infections, increasing alcohol consumption, and obesity contribute to the growing incidence of liver cancer, leading to heightened demand for effective diagnostic solutions. Early detection enhances treatment outcomes, thereby driving the need for advanced diagnostic technologies. Technological advancements present significant opportunities in the market. Innovations in imaging techniques, such as high-resolution MRI and advanced ultrasound technologies, provide more accurate and detailed visualization of liver tumors. Additionally, developing non-invasive diagnostic tests, such as liquid biopsies and molecular biomarkers, offers promising alternatives to traditional biopsy methods, improving patient comfort and diagnostic accuracy.

The growing emphasis on personalized medicine in oncology creates further opportunities for liver cancer diagnostics. Genetic and genomic testing advances allow for identifying specific tumor profiles and mutations, enabling tailored treatment approaches and improving patient management. This trend supports the demand for advanced diagnostic tools that provide comprehensive molecular and genetic information. Expanding healthcare infrastructure and increasing healthcare investments in emerging markets contribute to market growth. As these regions develop their healthcare systems and increase access to diagnostic technologies, the demand for liver cancer diagnostics is expected to rise. Moreover, the rise of awareness and education programs regarding liver cancer and its risk factors enhances early detection efforts. Public health initiatives that promote screening and early diagnosis further support market growth by increasing the adoption of diagnostic tests. However, high costs associated with advanced diagnostic technologies and limited access to healthcare in underserved regions can restrain market growth.

This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of liver cancer diagnostic.

Market Segmentation

The broad liver cancer diagnostic market has been sub-grouped into test type and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Test Type

Laboratory Tests (Biomarkers, Blood Tests)
Imaging
Endoscopy
Biopsy
Others

By End-use

Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & CRO Laboratories
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for liver cancer diagnostic in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Liver Cancer Diagnostic market includes Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A. Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIVER CANCER DIAGNOSTIC - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Test Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY TEST TYPE

5.1. Overview By Test Type
5.2. Historical and Forecast Data
5.3. Analysis By Test Type
5.4. Laboratory Tests (Biomarkers, Blood Tests) Historic and Forecast Sales By Regions
5.5. Imaging Historic and Forecast Sales By Regions
5.6. Endoscopy Historic and Forecast Sales By Regions
5.7. Biopsy Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Hospitals & Diagnostic Laboratories Historic and Forecast Sales By Regions
6.5. Academic & Research Institutes Historic and Forecast Sales By Regions
6.6. Pharmaceutical & CRO Laboratories Historic and Forecast Sales By Regions

7. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE LIVER CANCER DIAGNOSTIC COMPANIES

8.1. Liver Cancer Diagnostic Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF LIVER CANCER DIAGNOSTIC INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott Laboratories
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. F. Hoffmann-La Roche Ltd.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Qiagen N.V.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Thermo Fisher Scientific Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Siemens Healthineers
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Becton Dickinson & Company
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Illumina Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Koninklijke Philips N.V
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Epigenomics AG
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Fujifilm Medical Systems U.S.A. Inc.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments